Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

H.C. Wainwright analyst Patrick Trucchio says the selloff in shares of Altimmune (ALT) on the IMPACT readout appears overdone. The company ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

See Altimmune, Inc. (ALT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

The Dow traded up 0.82% to 43,335.29 while the NASDAQ gained 0.69% to 20,110.81. The S&P 500 also rose, gaining, 0.66% to ...

Despite calls for the meeting to be delayed, Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) went ahead.

Analysts collectively signal a bullish market with growth opportunities, showing confidence in strong corporate earnings, growth potential, and improving economic conditions, while recommending ...